The Hydrus Microstent in Pseudophakic Patients With Medically Refractory Open-angle Glaucoma

Area of Science:

• Ophthalmology
• Surgical Innovation

Background:

• Glaucoma is a leading cause of irreversible blindness.
• Medically refractory glaucoma requires advanced treatment strategies.
• Minimally invasive glaucoma surgery (MIGS) offers a less invasive approach to IOP reduction.

Purpose of the Study:

• To evaluate the efficacy and safety of the Hydrus Microstent in pseudophakic patients with medically refractory open-angle glaucoma.
• To document the use of this MIGS device in a previously undocumented patient population.

Main Methods:

• Retrospective case series of 11 pseudophakic eyes.
• Hydrus Microstent insertion for open-angle glaucoma refractory to 3+ medications.
• Postoperative follow-up at multiple intervals up to 60 months.

Main Results:

• Significant reduction in intraocular pressure (IOP) at 12 and 24 months (43.8% and 34.1% respectively).
• Substantial decrease in medication burden by 75.6% at 12 and 24 months.
• Transient complications included hyphaema and corneal epithelial defect, all resolved.

Conclusions:

• The Hydrus Microstent is effective in reducing IOP and medication requirements in pseudophakic patients with medically refractory open-angle glaucoma.
• This study highlights the Hydrus Microstent as a potential optimal therapeutic modality for this patient group.
• Further research is warranted to confirm long-term outcomes.